GO:0007168 receptor guanylyl cyclase signaling pathway: cGMP Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007168 describes signaling initiated when an extracellular ligand binds a cell-surface receptor that itself possesses guanylyl cyclase activity, converting GTP to cGMP.
• The receptor guanylyl cyclase family includes membrane-bound enzymes such as NPR-A (GC-A), NPR-B (GC-B), and GC-C, which are activated by natriuretic peptides, C-type natriuretic peptide, and guanylin/uroguanylin, respectively.
• cGMP produced by these receptors acts as a second messenger that regulates downstream effectors including cGMP-dependent protein kinases, phosphodiesterases, and ion channels.
• The pathway controls diverse physiological processes such as blood pressure, fluid homeostasis, cardiac remodeling, intestinal fluid secretion, and colon cancer prevention.
• Dysregulation of receptor guanylyl cyclase signaling is linked to cardiovascular disease, hypertension, heart failure, and colorectal cancer.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of receptor guanylyl cyclase gene function in health and disease.
Description
The receptor guanylyl cyclase signaling pathway (GO:0007168) is a fundamental signal transduction cascade in which an extracellular ligand binds to a cell-surface receptor that possesses intrinsic guanylyl cyclase activity, leading to the conversion of GTP to cyclic GMP (cGMP) and subsequent regulation of downstream cellular processes. This pathway is distinct from soluble guanylyl cyclase signaling because the receptor itself is the enzyme, coupling ligand recognition directly to second messenger production. The receptor guanylyl cyclase family was initially characterized in the early 1990s, establishing a unique class of transmembrane enzymes that function both as receptors and as catalysts. Since then, extensive research has elucidated the molecular architecture, regulatory mechanisms, and physiological roles of these receptors in cardiovascular, renal, and gastrointestinal systems. The pathway is critical for maintaining blood pressure, fluid and electrolyte balance, cardiac structure, and intestinal homeostasis. In the gastrointestinal tract, guanylyl cyclase C (GC-C) signaling suppresses colon cancer development, making it a target for chemoprevention. In the cardiovascular system, guanylyl cyclase A (GC-A), the receptor for atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), regulates blood pressure and cardiac hypertrophy. Genetic disruption of GC-A in mice leads to cardiac fibrosis and disorders in a sex-dependent manner, highlighting the pathway's importance in cardiac pathophysiology. The clinical relevance of this pathway extends to hypertension, heart failure, and colorectal cancer, where modulation of cGMP signaling offers therapeutic opportunities. Understanding the molecular details of receptor guanylyl cyclase signaling is therefore essential for developing targeted therapies and for interpreting genetic variants associated with disease.
receptor guanylyl cyclase signaling pathway At A Glance
| GO ID | GO:0007168 |
|---|---|
| GO term | receptor guanylyl cyclase signaling pathway |
| Ontology | biological_process |
| Synonym | cGMP signaling pathway; receptor guanylate cyclase signaling pathway; receptor guanylyl cyclase signalling pathway |
| Definition | The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses guanylyl cyclase activity, and converts GTP to cGMP upon activation, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduction of extracellular signals into intracellular cGMP production, regulating diverse physiological processes such as blood pressure, fluid homeostasis, and intestinal secretion. |
| Key receptors | Guanylyl cyclase A (GC-A/NPR-A), guanylyl cyclase B (GC-B/NPR-B), guanylyl cyclase C (GC-C), and other membrane-bound guanylyl cyclases. |
| Second messenger | Cyclic GMP (cGMP). |
| Downstream effectors | cGMP-dependent protein kinases (PKG), phosphodiesterases, cyclic nucleotide-gated channels. |
| Associated diseases | Hypertension, heart failure, cardiac fibrosis, colorectal cancer. |
What Is GO:0007168?
GO:0007168, receptor guanylyl cyclase signaling pathway, is defined as the series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses guanylyl cyclase activity, and converts GTP to cGMP upon activation, and ending with the regulation of a downstream cellular process, e.g. transcription. In simpler terms, it is a cell signaling cascade where the receptor itself is an enzyme that makes cGMP when it binds its ligand, and this cGMP then triggers changes inside the cell.
Why Is receptor guanylyl cyclase signaling pathway Important in Cell Biology?
The receptor guanylyl cyclase signaling pathway is essential for cardiovascular, renal, and gastrointestinal physiology, and its dysregulation contributes to major human diseases including hypertension, heart failure, and colorectal cancer. Because these receptors directly convert extracellular signals into the second messenger cGMP, they represent attractive drug targets, and understanding their function is critical for developing new therapies.
• Regulates blood pressure and fluid homeostasis through natriuretic peptide receptors GC-A and GC-B.
• Controls cardiac remodeling and fibrosis, with sex-dependent effects observed in GC-A knockout mice.
• Mediates intestinal fluid secretion and maintains gut homeostasis via GC-C.
• Suppresses colon cancer development through GC-C signaling, making it a chemoprevention target.
• Provides a paradigm for understanding receptor-enzyme coupling and cGMP-mediated signal transduction.
• Involved in metabolic processing and internalization of receptors, which affects signal duration and intensity.
• Offers therapeutic opportunities for cardiovascular and gastrointestinal disorders.
• Serves as a model system for studying membrane receptor trafficking and downregulation.
• Genetic variants in receptor guanylyl cyclase genes are associated with human diseases, necessitating functional studies.
• CRISPR-based editing enables precise modeling of pathway mutations for drug discovery.
What Happens During receptor guanylyl cyclase signaling pathway?
Ligand binding and receptor activation
In simple terms: A signaling molecule outside the cell binds to a receptor on the cell surface, turning the receptor on.
The pathway begins when an extracellular ligand, such as a natriuretic peptide or guanylin, binds to the extracellular domain of a receptor guanylyl cyclase. This binding induces conformational changes that activate the receptor's intracellular guanylyl cyclase domain. For example, atrial natriuretic peptide (ANP) binds to guanylyl cyclase A (GC-A), while guanylin and uroguanylin bind to guanylyl cyclase C (GC-C). The binding is highly specific and initiates the signaling cascade.
Enzymatic conversion of GTP to cGMP
In simple terms: The activated receptor acts as an enzyme that converts GTP into cGMP, a small molecule that carries the signal inside the cell.
Upon activation, the guanylyl cyclase domain of the receptor catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). This enzymatic activity is intrinsic to the receptor, distinguishing this pathway from soluble guanylyl cyclase signaling. The production of cGMP is rapid and transient, and its levels are tightly regulated by phosphodiesterases.
cGMP effector activation and downstream signaling
In simple terms: cGMP then activates other proteins inside the cell, such as protein kinases, which change cell behavior.
The newly synthesized cGMP binds to and activates downstream effectors, including cGMP-dependent protein kinases (PKG), cyclic nucleotide-gated ion channels, and phosphodiesterases. Activation of PKG leads to phosphorylation of target proteins that regulate smooth muscle relaxation, ion transport, and gene expression. In the intestine, cGMP activates PKGII and the cystic fibrosis transmembrane conductance regulator (CFTR), driving chloride and fluid secretion. The pathway can also regulate transcription factors, thereby influencing gene expression.
Receptor internalization and signal termination
In simple terms: After signaling, the receptor is taken into the cell and degraded or recycled, which stops the signal.
Following activation, receptor guanylyl cyclases undergo clathrin-dependent internalization, which contributes to signal termination and receptor downregulation. For guanylyl cyclase/natriuretic peptide receptor-A, internalization is linked to metabolic processing and trafficking to lysosomes or recycling to the plasma membrane. This process is critical for preventing excessive or prolonged signaling, and its dysregulation can contribute to disease.
Key Genes Involved in GO:0007168 receptor guanylyl cyclase signaling pathway
The following genes encode the major receptors, ligands, and downstream effectors of the receptor guanylyl cyclase signaling pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPR1 (GC-A) | Receptor guanylyl cyclase A; binds ANP and BNP; produces cGMP | Regulates blood pressure and cardiac hypertrophy; knockout mice show cardiac fibrosis |
| NPR2 (GC-B) | Receptor guanylyl cyclase B; binds CNP; produces cGMP | Regulates bone growth and vascular tone; mutations cause skeletal dysplasias |
| GUCY2C (GC-C) | Receptor guanylyl cyclase C; binds guanylin/uroguanylin; produces cGMP | Regulates intestinal fluid secretion; tumor suppressor in colon cancer |
| NPPA (ANP) | Ligand for GC-A; natriuretic peptide | Regulates blood pressure and fluid balance; biomarker for heart failure |
| NPPB (BNP) | Ligand for GC-A; natriuretic peptide | Biomarker and therapeutic target in heart failure |
| NPPC (CNP) | Ligand for GC-B; natriuretic peptide | Regulates endochondral ossification and vascular remodeling |
| GUCA2A (Guanylin) | Ligand for GC-C | Regulates intestinal secretion; downregulated in colon cancer |
| GUCA2B (Uroguanylin) | Ligand for GC-C | Regulates salt and water homeostasis; involved in obesity |
| PRKG1 (PKG I) | cGMP-dependent protein kinase I | Mediates smooth muscle relaxation and platelet inhibition |
| PRKG2 (PKG II) | cGMP-dependent protein kinase II | Mediates intestinal fluid secretion and bone growth |
| CFTR | Chloride channel; activated by cGMP/PKGII | Mediates chloride and fluid secretion in intestine |
| PDE5 | cGMP-specific phosphodiesterase | Degrades cGMP; target for erectile dysfunction and pulmonary hypertension |
| PDE6 | Photoreceptor phosphodiesterase | Regulates cGMP in retina; mutations cause retinal degeneration |
| GUCY2D | Retinal guanylyl cyclase 1 | Produces cGMP in photoreceptors; mutations cause Leber congenital amaurosis |
| GUCY2F | Retinal guanylyl cyclase 2 | Produces cGMP in photoreceptors |
| CNGA1 | Cyclic nucleotide-gated channel alpha 1 | Mediates cGMP-dependent ion flux in photoreceptors |
| CNGB1 | Cyclic nucleotide-gated channel beta 1 | Modulates CNG channel function in retina |
| SMAD2/3 | TGF-beta signaling effectors | Mediate cardiac fibrosis downstream of GC-A disruption |
How Is receptor guanylyl cyclase signaling pathway Regulated?
Receptor guanylyl cyclase signaling is regulated at multiple levels. Ligand availability and receptor expression levels control pathway activation. Receptor internalization and trafficking modulate signal duration; for NPR-A, clathrin-dependent internalization leads to metabolic processing and downregulation. Phosphodiesterases, particularly PDE5, degrade cGMP and terminate the signal. Additionally, cGMP levels are influenced by cross-talk with other signaling pathways, such as the TGF-beta/SMAD pathway, which is activated upon GC-A disruption in the heart. Post-translational modifications and interacting proteins also fine-tune receptor activity.
receptor guanylyl cyclase signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPR1 (GC-A) | Hypertension, heart failure, cardiac fibrosis | Knockout mouse; point-mutation knock-in for human variants |
| GUCY2C (GC-C) | Colorectal cancer, intestinal disorders | Knockout mouse; overexpression in colon cancer cell lines |
| GUCY2D | Leber congenital amaurosis, retinal degeneration | Knock-in mouse models; patient-derived iPSCs |
| NPR2 (GC-B) | Skeletal dysplasias, short stature | Knockout mouse; point-mutation knock-in |
| PRKG2 (PKG II) | Intestinal secretion disorders, bone abnormalities | Knockout mouse; conditional knockout |
Cardiovascular disease
The receptor guanylyl cyclase pathway is critically involved in cardiovascular homeostasis. GC-A (NPR1) mediates the effects of ANP and BNP, which lower blood pressure and inhibit cardiac hypertrophy. Genetic disruption of GC-A in mice leads to cardiac fibrosis and disorders in a sex-dependent manner, with activation of TGF-beta1/SMAD signaling. In humans, mutations in NPR1 are associated with hypertension and heart failure. The pathway is also a target for drugs such as sacubitril/valsartan, which increases natriuretic peptide levels.
Colorectal cancer
Guanylyl cyclase C (GC-C) signaling suppresses colon cancer development. Activation of GC-C by guanylin/uroguanylin leads to cGMP production, which inhibits cell proliferation and promotes differentiation. Loss of GC-C signaling, often due to downregulation of ligands, is observed in colorectal cancer. The pathway is considered a chemopreventive target, and agonists are being explored for therapy.
Retinal degeneration
In the retina, receptor guanylyl cyclases GUCY2D and GUCY2F produce cGMP essential for phototransduction. Mutations in GUCY2D cause Leber congenital amaurosis, a severe retinal dystrophy. The pathway is also involved in other retinal degenerations, highlighting its importance in vision.
From receptor guanylyl cyclase signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GC-A cause cardiac fibrosis? | NPR1 knockout mouse |
| How do human NPR1 mutations affect blood pressure? | Point-mutation knock-in mouse |
| Can GC-C activation prevent colon cancer? | GUCY2C overexpression in colon cancer cell lines |
| What is the role of GC-B in bone growth? | NPR2 knockout mouse |
| How does receptor internalization regulate signaling? | Tagged knock-in of NPR1 with fluorescent tag |
| Does cGMP signaling regulate intestinal fluid secretion? | PRKG2 knockout mouse |
How to Study the receptor guanylyl cyclase signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cGMP immunoassay | Intracellular cGMP levels | Quantify receptor guanylyl cyclase activity |
| CRISPR knockout | Gene function loss | Study pathway role in disease models |
| Knock-in point mutation | Effect of specific variants | Model human mutations |
| Live-cell imaging | Receptor internalization and trafficking | Study signal termination |
| RNA-seq | Transcriptional changes | Identify downstream targets |
| Proteomics | Protein expression and modifications | Analyze signaling networks |
| Western blot | Protein levels and phosphorylation | Validate pathway activation |
| Luciferase reporter | Transcriptional activity | Measure downstream gene regulation |
Biochemical assays for cGMP
cGMP levels can be measured using enzyme immunoassays or mass spectrometry to assess receptor guanylyl cyclase activity. These methods are used to quantify pathway activation in response to ligands or genetic manipulation.
Genetic knockout and knock-in models
CRISPR/Cas9-mediated knockout of receptor guanylyl cyclase genes in mice or cell lines allows functional studies. Knock-in of specific point mutations enables modeling of human disease variants.
Imaging and trafficking studies
Fluorescent tagging of receptors combined with live-cell imaging reveals internalization and trafficking dynamics. This approach has been used to study clathrin-dependent internalization of NPR-A.
Transcriptomics and proteomics
RNA-seq and proteomics can identify downstream transcriptional and signaling changes following pathway activation or disruption. For example, TGF-beta/SMAD signaling components are upregulated in GC-A knockout hearts.
How CRISPR Can Be Used to Study GO:0007168 receptor guanylyl cyclase signaling pathway
Knockout
CRISPR knockout of receptor guanylyl cyclase genes such as NPR1, NPR2, or GUCY2C in cell lines or animal models abolishes pathway activity, enabling studies of loss-of-function phenotypes. For example, NPR1 knockout mice develop cardiac fibrosis and hypertension.
Point Mutation
Introducing specific point mutations via CRISPR base editing or homology-directed repair allows modeling of human disease-associated variants in receptor guanylyl cyclase genes. This approach can reveal how mutations affect ligand binding, enzymatic activity, or downstream signaling.
Knock-in
Knock-in of tagged receptors (e.g., GFP or HA) enables visualization and biochemical isolation of receptor complexes. Knock-in of human disease alleles into mouse models provides physiologically relevant systems.
Overexpression
Overexpression of receptor guanylyl cyclases or their ligands using CRISPR activation or lentiviral vectors can enhance pathway activity, useful for studying gain-of-function effects and for drug screening.
How EDITGENE Supports receptor guanylyl cyclase signaling pathway Research
Researchers studying receptor guanylyl cyclase signaling pathway-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cardiac fibrosis or colon cancer suppression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of pathway components.
Contact EDITGENE today to design your custom CRISPR model for receptor guanylyl cyclase signaling pathway research.
Frequently Asked Questions About receptor guanylyl cyclase signaling pathway
What is the receptor guanylyl cyclase signaling pathway?
It is a cell signaling cascade where an extracellular ligand binds to a cell-surface receptor that itself is an enzyme converting GTP to cGMP, which then regulates downstream cellular processes.
What genes are involved in receptor guanylyl cyclase signaling?
Key genes include NPR1 (GC-A), NPR2 (GC-B), GUCY2C (GC-C), NPPA, NPPB, NPPC, GUCA2A, GUCA2B, PRKG1, PRKG2, and CFTR.
What is the role of cGMP in receptor guanylyl cyclase signaling?
cGMP is the second messenger produced by the receptor's enzymatic activity; it activates protein kinases, ion channels, and phosphodiesterases to propagate the signal.
How is receptor guanylyl cyclase signaling regulated?
It is regulated by ligand availability, receptor internalization and trafficking, phosphodiesterase-mediated cGMP degradation, and cross-talk with other pathways such as TGF-beta/SMAD.
What diseases are associated with receptor guanylyl cyclase signaling?
Dysregulation is linked to hypertension, heart failure, cardiac fibrosis, colorectal cancer, and retinal degeneration.
What is the difference between receptor and soluble guanylyl cyclase?
Receptor guanylyl cyclases are membrane-bound receptors with intrinsic enzymatic activity, while soluble guanylyl cyclases are cytoplasmic enzymes activated by nitric oxide.
How can CRISPR be used to study receptor guanylyl cyclase signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of pathway genes to study their function in health and disease.
What is the role of GC-C in colon cancer?
GC-C signaling suppresses colon cancer development by inhibiting proliferation and promoting differentiation; loss of this signaling is observed in colorectal cancer.
What is the role of GC-A in the heart?
GC-A mediates the effects of ANP and BNP to lower blood pressure and inhibit cardiac hypertrophy; its disruption leads to cardiac fibrosis.
What experimental models are available for receptor guanylyl cyclase research?
Models include knockout mice, point-mutation knock-in mice, tagged knock-in cell lines, overexpression cell lines, and patient-derived iPSCs.
Conclusion
The receptor guanylyl cyclase signaling pathway (GO:0007168) is a vital signal transduction mechanism that converts extracellular cues into the second messenger cGMP, regulating cardiovascular, renal, and gastrointestinal physiology. Its dysregulation contributes to major diseases including hypertension, heart failure, and colorectal cancer, making it a key target for therapeutic development. Advances in CRISPR-based genome editing now enable precise modeling of pathway components, accelerating functional studies and drug discovery. Continued research into this pathway will likely yield new insights and treatments for related disorders.
References
- 1. Prasad H et al.. 2022. Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities.. Front Endocrinol (Lausanne) 13:911459 PMID: 35846281
- 2. Somanna NK et al.. 2018. Clathrin-dependent internalization, signaling, and metabolic processing of guanylyl cyclase/natriuretic peptide receptor-A.. Mol Cell Biochem 441(1-2):135-150 PMID: 28900772
- 3. Pattison AM et al.. 2016. Guanylyl cyclase C signaling axis and colon cancer prevention.. World J Gastroenterol 22(36):8070-7 PMID: 27688649
- 4. Klaiber M et al.. 2011. A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide.. Proc Natl Acad Sci U S A 108(45):18500-5 PMID: 22027011
- 5. Garbers DL et al.. 1994. Guanylyl cyclase receptors.. Mol Biol Cell 5(1):1-5 PMID: 7910495
- 6. Garbers DL. 1990. The guanylyl cyclase receptor family.. New Biol 2(6):499-504 PMID: 1982420
- 7. Potter LR. 2011. Guanylyl cyclase structure, function and regulation.. Cell Signal 23(12):1921-6 PMID: 21914472
- 8. Subramanian U et al.. 2022. Genetic Disruption of Guanylyl Cyclase/Natriuretic Peptide Receptor-A Triggers Differential Cardiac Fibrosis and Disorders in Male and Female Mutant Mice: Role of TGF-β1/SMAD Signaling Pathway.. Int J Mol Sci 23(19) PMID: 36232788
